Australia markets close in 5 hours 2 minutes

electroCore, Inc. (43E.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.8135-0.0330 (-3.90%)
At close: 3:56PM CEST
Full screen
Previous close0.8465
Open0.8120
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.8120 - 0.8135
52-week range0.8120 - 0.8135
Volume20,000
Avg. volumeN/A
Market cap26.678M
Beta (5Y monthly)1.17
PE ratio (TTM)N/A
EPS (TTM)-0.3530
Earnings date04 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est3.55
  • GlobeNewswire

    electroCore to Announce Third Quarter 2021 Financial Results on Thursday, November 4th

    ROCKAWAY, NJ, Oct. 21, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third quarter ended September 30, 2021 after the close of the market on Thursday, November 4, 2021. Management will host a conference call and webcast at 4:30pm Eastern Time to discuss the financial results and answer questions. Thursday, November 4, 2021, 4:30pm Eastern TimeDomestic: 877-269-7756International

  • GlobeNewswire

    electroCore Announces Publication Reviewing the Prescribing of gammaCore for the Treatment of Cluster Headache in England

    ROCKAWAY, NJ, Oct. 20, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper entitled “Non-invasive vagus nerve stimulation for treatment of cluster headache: a retrospective review of prescribing in England,” in the British Journal of Healthcare Management. The paper reviews the prescribing trends of gammaCore in England from April 2019 through the end of 2020. gammaCore was listed o

  • GlobeNewswire

    electroCore Announces Regulatory Approval in Canada to Treat Adolescent Migraine

    Health Canada expands gammaCore label to include the acute and preventive treatment of migraine in adolescentsROCKAWAY, NJ, Oct. 14, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that the company received an amended Medical Device License from Health Canada to expand the label of gammaCore nVNS to include the acute and preventive treatment of migraine in adolescents between 12 and 17 years of age. gammaCore is now cl